Evidence review
Zepbound and Wegovy Side Effects: What Helps When You're Running a Household
Zepbound and Wegovy side effects by the label numbers, dose by dose, what helps with nausea and constipation, and the symptoms that mean call your clinician.
Written by Elena Voss, Metabolic Health EditorUpdated
On this page
- The short version
- How common, actually — with the placebo arm next to it
- What are Zepbound's side effects, dose by dose?
- Why it happens, and why the timing is predictable
- Nausea: the one most mothers feel first
- Constipation and reflux: the quieter two
- Protecting muscle while your appetite is low
- The red flags: when to stop grinding and call someone
- When side effects mean "adjust," not "quit"
- Where this sits on the evidence scale
The short version
Most GLP-1 side effects are gastrointestinal, most are mild to moderate, and most cluster during the weeks you're moving up to a higher dose rather than at a steady maintenance dose. In the pivotal semaglutide obesity trial, nausea and diarrhea were the most common adverse events, typically transient and mild-to-moderate, and they subsided with time — 4.5% of the semaglutide group stopped because of gastrointestinal events, against 0.8% on placebo1. Tirzepatide's pivotal trial (the drug in Zepbound) showed the same pattern: gastrointestinal events most common, most mild to moderate, occurring primarily during dose escalation2. For a mother the practical question is rarely "should I stop"; it's how to get through the dose-increase weeks without derailing the school run and dinner. Most answers are behavioral, and a few symptoms are red flags that mean a same-day call.
Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Every clinical figure here is cited inline to its primary source, the trial or the FDA label, so you can check it. This is background reading, not medical advice.
How common, actually — with the placebo arm next to it
Plenty of people report nausea on a placebo injection too, so a rate needs its comparison arm. The Wegovy label pools three randomized, double-blind, placebo-controlled weight-reduction trials in adults — 2,116 on 2.4 mg weekly against 1,261 on placebo, mean age 48, 71% female — about as close to this site's reader as published safety data gets5.
| Adverse reaction | Wegovy 2.4 mg injection (n=2,116) | Placebo (n=1,261) |
|---|---|---|
| Nausea | Wegovy 2.4 mg injection (n=2,116): 44% | Placebo (n=1,261): 16% |
| Diarrhea | Wegovy 2.4 mg injection (n=2,116): 30% | Placebo (n=1,261): 16% |
| Vomiting | Wegovy 2.4 mg injection (n=2,116): 24% | Placebo (n=1,261): 6% |
| Constipation | Wegovy 2.4 mg injection (n=2,116): 24% | Placebo (n=1,261): 11% |
| Abdominal pain | Wegovy 2.4 mg injection (n=2,116): 20% | Placebo (n=1,261): 10% |
| Fatigue | Wegovy 2.4 mg injection (n=2,116): 11% | Placebo (n=1,261): 5% |
| Hair loss | Wegovy 2.4 mg injection (n=2,116): 3% | Placebo (n=1,261): 1% |
Read the placebo column before you panic at the drug column: one in six reported nausea on placebo. Two more figures set the scale. Severe gastrointestinal reactions — not the everyday kind — occurred in 4.1% of adults on the injection against 0.9% on placebo, and 6.8% stopped treatment for an adverse reaction against 3.2% on placebo5. The common experience is unpleasant and manageable; the treatment-ending one is the minority.
What are Zepbound's side effects, dose by dose?
The Zepbound label splits its numbers by dose, which shows what each step up tends to cost. It pools two placebo-controlled weight-loss trials of up to 72 weeks: 2,519 adults on Zepbound and 958 on placebo, 63% of them women6.
| Adverse reaction | Placebo | Zepbound 5 mg | Zepbound 10 mg | Zepbound 15 mg |
|---|---|---|---|---|
| Nausea | Placebo: 8% | Zepbound 5 mg: 25% | Zepbound 10 mg: 29% | Zepbound 15 mg: 28% |
| Diarrhea | Placebo: 8% | Zepbound 5 mg: 19% | Zepbound 10 mg: 21% | Zepbound 15 mg: 23% |
| Vomiting | Placebo: 2% | Zepbound 5 mg: 8% | Zepbound 10 mg: 11% | Zepbound 15 mg: 13% |
| Constipation | Placebo: 5% | Zepbound 5 mg: 17% | Zepbound 10 mg: 14% | Zepbound 15 mg: 11% |
| Indigestion (dyspepsia) | Placebo: 4% | Zepbound 5 mg: 9% | Zepbound 10 mg: 9% | Zepbound 15 mg: 10% |
| Injection site reactions | Placebo: 2% | Zepbound 5 mg: 6% | Zepbound 10 mg: 8% | Zepbound 15 mg: 8% |
| Fatigue | Placebo: 3% | Zepbound 5 mg: 5% | Zepbound 10 mg: 6% | Zepbound 15 mg: 7% |
| Burping (eructation) | Placebo: 1% | Zepbound 5 mg: 4% | Zepbound 10 mg: 5% | Zepbound 15 mg: 5% |
| Hair loss | Placebo: 1% | Zepbound 5 mg: 5% | Zepbound 10 mg: 4% | Zepbound 15 mg: 5% |
| Reflux (GERD) | Placebo: 2% | Zepbound 5 mg: 4% | Zepbound 10 mg: 4% | Zepbound 15 mg: 5% |
Three things stand out. Gastrointestinal reactions of any kind hit 56% at every dose against 30% on placebo, and most nausea, vomiting and diarrhea came during dose escalation and eased over time. Vomiting climbs with dose while constipation falls, so the higher step is not uniformly worse. And 4.8% to 6.7% stopped for a side effect, against 3.4% on placebo, mostly in the first few months6.
The figure women should know: hair loss was reported by 7.1% of women on Zepbound against 0.5% of men, and the label ties it to weight reduction. No one on Zepbound stopped treatment for it6. Our hair loss guide covers what helps.
One more for mothers on the pill: because Zepbound slows stomach emptying, the label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and 4 weeks after each dose increase6. Our birth control guide explains why. The label also warns that rates from one drug's trials cannot be lined up directly against another's, so read the Wegovy and Zepbound tables side by side, not as a contest.
Why it happens, and why the timing is predictable
GLP-1 (and the dual GIP/GLP-1 tirzepatide) medications slow how fast the stomach empties and turn down appetite signaling. That is part of why they work, and also why fullness tips into nausea, reflux, or constipation3. Nausea spikes after a step up and settles as your body adapts, which is why a good program titrates slowly. Constipation is the exception: it doesn't climb with dose, so waiting out the next step up won't fix it.
Nausea: the one most mothers feel first
A multidisciplinary expert consensus sets out the core advice: eat slowly, only when genuinely hungry, smaller portions more often, stop at the feeling of fullness rather than finishing the plate, avoid lying down after a meal, and don't eat close to bedtime3. What that looks like in real life:
- Eat before you're ravenous, and stop early. Your fullness cue arrives fast and hard; the overshoot is what turns into nausea.
- Downshift fat and volume during dose-increase weeks. Rich or very large meals sit heaviest when your stomach is already emptying slowly3.
- Keep sipping fluids. It's easy to under-drink when you're not hungry, and dehydration makes nausea worse.
- Time the dose to your week. Inject on a day when a rough evening is easiest to absorb.
If nausea is severe or you can't keep fluids down, ask your prescriber about slowing the titration or anti-nausea support.
Constipation and reflux: the quieter two
Slowed gut motility cuts both ways. For constipation the consensus is straightforward: increase mobility, water and fiber, and consider a stool softener if diet alone isn't enough — the panel notes people drink less once the drug makes them feel full, part of why it sets in3. Worth knowing before you self-treat: the same consensus points fiber the opposite way for diarrhea, temporarily reducing high-fiber foods until symptoms settle3. "Eat more fiber" is right for one and wrong for the other.
Reflux and that "food still sitting there" heaviness respond to smaller, more frequent meals, avoiding foods that relax the lower esophageal sphincter — fatty, fried or processed foods, tomato, mint, chocolate — and not lying down after eating3.
Protecting muscle while your appetite is low
When appetite drops this hard, protein is the first thing to fall, and under-eating it during rapid weight loss costs muscle and worsens fatigue, reported by 11% on Wegovy against 5% on placebo5. Put protein first at each smaller meal and keep up resistance movement; it protects muscle and bone density too.
The red flags: when to stop grinding and call someone
Most side effects are nuisances that fade. A short list are not, and the FDA labeling for these drugs flags them explicitly — persistent severe abdominal pain (which can radiate to the back and may signal pancreatitis), signs of gallbladder trouble, and dehydration serious enough to affect kidney function all warrant prompt medical attention5. Most reported acute kidney injury followed vomiting or diarrhea severe enough to dehydrate, which is why "keep fluids up" is a safety instruction5.
Gallbladder and biliary disease is the best-quantified of these. A meta-analysis of 76 randomized trials in 103,371 patients found GLP-1 use associated with more gallbladder or biliary disease (RR 1.37, 95% CI 1.23–1.52), larger at higher doses and with longer use. The 13 trials run for weight loss showed a larger effect (RR 2.29, 95% CI 1.64–3.18) than the 63 for diabetes and other indications (RR 1.27)4. In absolute terms on the adult label, cholelithiasis was reported by 1.6% on Wegovy injection versus 0.7% on placebo, and cholecystitis by 0.6% versus 0.2% — and the excess persisted after accounting for weight lost, so it isn't purely a rapid-weight-loss effect5. Zepbound's label shows the same direction: cholecystitis in 0.7% against 0.2% on placebo6. Uncommon, then, but genuinely more likely on the drug and at the doses used for weight. So the rule of thumb:
- Same-day call: severe or persistent abdominal pain, repeated vomiting with inability to keep fluids down, signs of dehydration, or symptoms of gallbladder disease (upper-right abdominal pain, fever, yellowing of the skin or eyes)5.
- Routine check-in: side effects that are tolerable but not improving after a few weeks at a dose, or any symptom interfering with caring for your kids.
When side effects mean "adjust," not "quit"
If the dose-increase weeks are consistently rough, the answer is often a gentler slope: slower titration, holding a dose longer, or a smaller starting dose. If you're weighing the two molecules on tolerability, our semaglutide vs tirzepatide guide compares them. The goal is a pace you can live with while running a household — and, in time, a plan for coming off or maintaining that doesn't undo the work.
Where this sits on the evidence scale
High on how common these are and what the danger signs mean. Both labels print the placebo arm beside the drug arm from large randomized, double-blind trials, two pivotal trials show the same escalation-weighted pattern, and the gallbladder signal comes from a meta-analysis of 76 randomized trials with a larger effect in weight-loss trials.
Lower on what to do about them. The food-and-pacing advice is an expert consensus, not a trial; nobody has randomized people to "eat slowly" during titration. Treat it as sensible and unproven, and the frequency numbers and red-flag list as solid.
Providers to compare
All provider reviews- Form Health86/100Mothers who want physician-led obesity medicine and a dietitian in the loop, and don't mind monthly video visits and a medication cost billed on top of the membership.Read the review
- Gala HealthPartner84/100Mothers who want both molecules at a price that holds at every dose, and are comfortable committing to a yearly plan to get the advertised rate.Read the review
- Calibrate69/100A mom with employer insurance that covers brand GLP-1s, done with nursing and not planning another baby this year, who wants one-on-one coaching and a real clinician on video.Read the review
- 9amHealth63/100Mothers managing diabetes alongside weight who want a genuine multidisciplinary care team and brand-only medication, and who may qualify for the insurance route.Read the review
- EdenPartner47/100A mom for whom the monthly number decides it, and who will read what the FDA letter actually alleges before deciding it does not change her answer.Read the review
Frequently asked questions
What are the most common Zepbound side effects?
Nausea, diarrhea, vomiting, constipation, indigestion, injection site reactions, fatigue, burping, hair loss and reflux, per the Zepbound label. Nausea ran 25% to 29% across the 5, 10 and 15 mg doses against 8% on placebo, and most stomach symptoms came while the dose was being raised and eased afterward. Hair loss was reported by 7.1% of women on Zepbound against 0.5% of men.
Are Zepbound side effects worse than Wegovy's?
The labels cannot settle it. Each comes from its own trials, and the Zepbound label itself warns that rates from one drug's trials cannot be compared directly with another's. On their own labels, nausea was 44% on Wegovy 2.4 mg against 16% on placebo, and 25% to 29% on Zepbound against 8% on placebo. A head-to-head trial, not two tables, is what would answer it.
When do GLP-1 side effects usually hit the hardest?
In the days after a dose increase. These drugs slow how fast your stomach empties, so nausea and reflux tend to spike right after you step up a dose and then settle as your body adapts. That's why slow titration matters — rushing to the top dose to chase faster weight loss usually just means rougher weeks. Constipation is the exception: in the trial data it does not rise with dose the way nausea, vomiting and diarrhea do, so it is better treated as its own problem than waited out.
What actually helps with the nausea day to day?
Smaller portions, stopping at the first sign of fullness, favoring blander and lower-fat foods over greasy or very large meals, eating slowly, not lying down right after eating, and keeping fluids up. Many mothers also time their weekly dose to a day when a rough evening is easiest to absorb. If you can't keep fluids down, that's a call to your prescriber about slowing the dose, not something to push through.
Which symptoms mean I should call a clinician right away?
Severe or persistent abdominal pain (especially if it radiates to your back), repeated vomiting where you can't keep fluids down, signs of dehydration, or gallbladder symptoms like upper-right abdominal pain, fever, or yellowing of the skin or eyes. GLP-1s carry a real if uncommon gallbladder-disease risk, and the labels flag pancreatitis and kidney effects — those warrant a same-day call, not waiting it out.
References
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine. https://pubmed.ncbi.nlm.nih.gov/36614945/
- He L, Wang J, Ping F, et al. (2022). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/35344001/
- Novo Nordisk / U.S. Food and Drug Administration (2026). WEGOVY (semaglutide) — Prescribing Information (5.2 Acute Pancreatitis; 5.3 Acute Gallbladder Disease; 5.5 Acute Kidney Injury Due to Volume Depletion; 5.6 Severe Gastrointestinal Adverse Reactions; 6.1 Table 3, adverse reactions in adults vs placebo). SPL version 19, effective 18 June 2026. DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Eli Lilly and Company / U.S. Food and Drug Administration (2026). ZEPBOUND (tirzepatide) — Prescribing Information (6.1 Table 1, adverse reactions by dose vs placebo; gastrointestinal adverse reactions; hair loss by sex; acute gallbladder disease; 7.2 oral contraceptives). SPL version 40, effective 28 August 2026. DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
Background reading, not medical advice. MomMetabolic summarizes published research and FDA labeling for mothers weighing GLP-1 care. It cannot diagnose you, cannot account for your history or hormones, and is no substitute for a licensed clinician who can. Decisions to begin, adjust, pause, or stop any medication belong with your own prescriber.
Continue reading
Wegovy for Teens: Eligibility, Trial Results and Parent Questions
What the Wegovy injection label and STEP TEENS trial show for adolescents with obesity, plus parent questions about follow-up, safety and long-term care.
ReadGLP-1s and Surgery: What the Aspiration Evidence Actually Shows
Food is left in the stomach far more often despite correct fasting, yet no rise in actual aspiration has been detected. Both are true, and the gap matters.
ReadSleep Apnea, GLP-1s, and Why Women Get Missed
Zepbound cut apnea events by 20 to 24 an hour more than placebo across two trials. The harder problem is that women with sleep apnea rarely get diagnosed.
Read